TY - JOUR T1 - 平均，最好，最差和电流强度最小临床上重要的差异和不愉快慢性呼吸困难的JF - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.02202-2019 VL - 56 - 2 SP - 1902202 AU- 埃克斯特罗姆，马格努斯AU - 约翰逊，杨千嬅J. AU - 黄，超AU - Currow，大卫C. Y1 - 2020年8月1日UR - //www.qdcxjkg.com/content/56/2/1902202。抽象N2 - 背景慢性呼吸困难已造成灾难性的后果。The minimal clinically important difference (MCID) for current intensity has been estimated as 9 mm on a 100-mm visual analogue scale (VAS). We aimed to determine MCIDs for commonly used dimensions and recall periods: the current unpleasantness and current, average, best and worst intensity of the past 24 h for chronic breathlessness.Methods This was a secondary analysis of a randomised controlled trial of morphine versus placebo over 7 days in people with chronic breathlessness from severe disease. The breathlessness scores were self-reported using a diary each evening on 100-mm VAS. The MCID for improvement in each score was estimated using anchor-based and distribution-based methods.Results 283 participants (mean age 74.2 years; 63% male; 58% COPD; 87.0% modified Medical Research Council (mMRC) score 3–4) were included. Anchor-based MCIDs for breathlessness scores ranged from −13.9 mm to −9.5 mm. The MCIDs were similar when using different anchors and across all participants, and participants with more severe breathlessness (mMRC 3–4). Distribution-based effect sizes were classed as small (−4.7−6.3 mm), moderate (−9.4−12.5 mm) and large (−15.0−20.0 mm) effect. Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.Conclusion An improvement of ∼10 mm on a 100-mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the past 24 h) to evaluate clinical benefit and effects in therapeutic trials.This cohort study determined clinically important differences for current intensity and unpleasantness and the average, best and worst intensity of the past 24 h of chronic breathlessness, which is important for the design of therapeutic trials https://bit.ly/3amslss ER -